Skip to main content

Table 1 Major immune components of STIE and TIME

From: Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors

Cancer

type

STIE

TIME

REF

Cell

Immune regulator

Cell

Immune regulator

NSCLC

↑: CD8+ GranB+T, Naïve CD4+, CD4+NKT, Ter cell, NK, Cytolytic CD16+NK, CD14+ monocyte, basophil

-: Neutrophil, CD16+ monocyte

↓: CD8+PD-1+T, CD8+T CM, Treg, CD1c+DC, Macrophage, Eosinophil, Mast cell

↑: TGF-β1, IDO, Artemin, PD-1, PD-L1, CTLA-4, GITR, IL-17

↓: BMI1

↑: CD8+PD-1+ T, CD8+ T CM, Treg, Infiltrated CXCR3+NK, CD1c+DC

-: Naïve CD4+, Macrophage, CD14+monocyte, Neutrophil, Eosinophil

↓: CD8+ GranB+T, CD16+monocyte, NK, CD4+NKT, Cytolytic CD16+NK, Basophil, Mast cell

↑: TGF-β1, CTLA4, CD11c, CD14, CD39, ICOS, 41BB, IL-6, PPARγ

↓: IL-8, IL-1β, IFN-γ, Granzyme B, CD57, CD86, CD206

[29,30,31,32,33,34,35,36,37,38,39,40] [29]*

HCC

↑: Treg, MDSC

↓: CD8+ T, CD4+ T

↑: PD-L1, IL-6, LAYN

↓: PD-1, CTLA4, IFN-γ, LAG3, TIM3, PTPRO

↑: CD8+T, CD4+T, Treg, B cell, Monocyte, DC, Kupffer cell, Neutrophil

↓: NK, NKT

↑: PD-1, PD-L1, CTLA4, TIM3, LAG3, IFN-γ, IL-10, IgA

↓: CCL4, CCL14

[41,42,43,44,45,46,47,48,49,50,51,52,53,54,55]

NPC

↑: NK, PD-1+ NK

-: Treg

↓: CD8+T, CD4+T, B cell

↑: IL-2, IL-10, IL-18, MMP-9, CR1, IgM

↑: CD8+ T, Treg, B cell, PD-1+CXCR5CD4+ Th-CXCL13,

CD19+ B cell

↓: NK

↑: PD-1, FOXP3, LAG3, HAVCR2, IFN-γ, IL2RA, IL-18, IL-21, CCL19, CCL20, CXCL10, CXCL13

[56,57,58,59,60,61,62,63,64,65]

  1. ↑, Upregulation; ↓, Downregulation; -, symbol No significant change in the cited literature studies; ↑, ↓ and - reflected the changes in tumor tissue or cancer patients compared with adjacent normal tissue or non-cancer donors; *: Compared with tumor tissue; T T cells, TCM central memory T cell, NK natural killer, NKT natural killer T cell, DC dendritic cell, REF reference. NSLC non-small cell lung cancer, HCC hepatocellular carcinoma, and NPC nasopharyngeal cancer are shown as examples